The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Celecoxib for the prevention of sporadic colorectal adenomas.
Studies showing that drugs that inhibit cyclooxygenase-2 (COX-2) reduce the number of colorectal adenomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may also prevent sporadic colorectal neoplasia. ⋯ These findings indicate that celecoxib is an effective agent for the prevention of colorectal adenomas but, because of potential cardiovascular events, cannot be routinely recommended for this indication. (ClinicalTrials.gov number, NCT00005094 [ClinicalTrials.gov].).
-
Randomized Controlled Trial Multicenter Study Comparative Study
A randomized trial of deep-brain stimulation for Parkinson's disease.
Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's disease. We compared this treatment plus medication with medical management. ⋯ In this six-month study of patients under 75 years of age with severe motor complications of Parkinson's disease, neurostimulation of the subthalamic nucleus was more effective than medical management alone. (ClinicalTrials.gov number, NCT00196911 [ClinicalTrials.gov].).
-
Randomized Controlled Trial Multicenter Study
Celecoxib for the prevention of colorectal adenomatous polyps.
Overexpression of cyclooxygenase 2 (COX-2) has been associated with colorectal adenomatous polyps and cancer, prompting researchers to propose its inhibition as a chemopreventive intervention. ⋯ The use of 400 mg of celecoxib once daily significantly reduced the occurrence of colorectal adenomas within three years after polypectomy. (ClinicalTrials.gov number, NCT00141193 [ClinicalTrials.gov].).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Alternative therapies for Staphylococcus aureus bacteremia and endocarditis are needed. ⋯ Daptomycin (6 mg per kilogram daily) is not inferior to standard therapy for S. aureus bacteremia and right-sided endocarditis. (ClinicalTrials.gov number, NCT00093067 [ClinicalTrials.gov].).
-
Randomized Controlled Trial Comparative Study
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. ⋯ During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. (ClinicalTrials.gov number, NCT00138983 [ClinicalTrials.gov].).